At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 12 enrolled
Drug / intervention
ER Morphine +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A CTSC Clinical Research Center Study: A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine
In Brief
A Phase 4 clinical trial evaluating Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity, ER Morphine, and 2 other interventions for Chronic Pain. Completed, enrolled 12 participants.
Detailed Summary
Characterize the relative abuse liability of a short versus a long acting opioid in chronic pain patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Pain
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2005
First PostedApr 2006
Primary CompletionApr 2008
TodayJul 2026
First PostedApr 13, 2006
Enrollment StartNov 1, 2005
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 20.2 years ago
Interventions
Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivitybehavioral
The first dose of the study medication was taken following collection of baseline measurements, and subsequent measurements were taken hourly thereafter. Respiration, heart rate, arterial oxygen saturation (pulse oximetry), and blood pressure were also monitored at these intervals to insure the safety of subjects.
ER Morphinedrug
hydrocodone plus acetaminophendrug
placebodrug